Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride
Brand Name
Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride
Generic Name
Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride
Active Ingredient
Bismuth SubcitrateCategory
Nitroimidazole Antimicrobial [EPC]
Salt Form
Potassium
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 140 mg/1 | CAPSULE | ORAL | 50742-283 |
Detailed information about Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride, you must consult a qualified healthcare professional.
Bismuth Subcitrate is a gastroprotective and antimicrobial agent primarily used in combination therapy to eradicate Helicobacter pylori infections. It belongs to the bismuth-containing mucosal protective class and exhibits direct bactericidal effects against gastric pathogens.
The dosage of Bismuth Subcitrate Potassium is highly standardized when used for the eradication of H. pylori. According to clinical guidelines from the American College of Gastroenterology (ACG):
Bismuth Subcitrate Potassium is generally not recommended for children or adolescents under the age of 18. This is primarily due to the risk of Reye’s syndrome (though this risk is higher with bismuth subsalicylate) and the lack of robust clinical trials for the subcitrate salt in pediatric populations. If a healthcare provider deems it necessary for a child with refractory H. pylori, the dose is strictly calculated based on weight and surface area, usually in a specialized hospital setting.
Bismuth is cleared by the kidneys. In patients with mild to moderate renal impairment, Bismuth Subcitrate should be used with extreme caution. It is strictly contraindicated in patients with severe renal impairment (Creatinine Clearance < 30 mL/min), as bismuth can accumulate to toxic levels, leading to nephrotoxicity and encephalopathy.
Since bismuth is not metabolized by the liver, no specific dose adjustments are typically required for patients with hepatic impairment. However, because it is often co-administered with metronidazole (which is liver-metabolized), the overall regimen may need adjustment by a specialist.
Clinical trials have not shown significant differences in safety between elderly and younger patients. However, because elderly patients are more likely to have decreased renal function, a baseline Creatinine Clearance test is recommended before starting therapy.
To ensure maximum efficacy and safety, patients should follow these administration guidelines:
If you miss a dose, take it as soon as you remember. If it is nearly time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. Completing the full 10-to-14-day course is critical; stopping early can lead to antibiotic resistance and treatment failure.
Signs of acute bismuth overdose include:
In the event of an overdose, seek emergency medical attention immediately. Treatment usually involves gastric lavage (stomach pumping), administration of activated charcoal, and in severe cases, chelation therapy or hemodialysis to remove bismuth from the blood.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication early without medical guidance, as H. pylori is difficult to eradicate and requires the full course of therapy.
Most patients taking Bismuth Subcitrate will experience some side effects, which are generally benign but can be startling if unexpected.
While rare at standard doses, serious complications can occur, particularly if the drug accumulates due to renal failure or prolonged use.
> Warning: Stop taking Bismuth Subcitrate and call your doctor immediately if you experience any of these:
Bismuth Subcitrate is intended for short-term use (10-14 days). Prolonged use (months to years) is strictly discouraged due to the risk of:
There are currently no FDA black box warnings specifically for Bismuth Subcitrate Potassium as a standalone agent. However, when used in combination products like Pylera, the label contains warnings regarding the potential for metronidazole to be carcinogenic in mice and rats, and the risk of permanent tooth discoloration in children associated with tetracycline.
Report any unusual symptoms, especially neurological changes or severe skin reactions, to your healthcare provider immediately.
Bismuth Subcitrate is a potent medication that must be used strictly according to clinical protocols. The most critical safety consideration is the duration of therapy; it is not intended for long-term management of acid reflux or indigestion. Patients must be screened for pre-existing kidney disease, as this is the primary risk factor for bismuth toxicity.
No FDA black box warnings for Bismuth Subcitrate. However, patients should be aware that the combination therapies it is part of carry significant warnings regarding antibiotic resistance and fetal harm.
For a standard 10-to-14-day course, extensive monitoring is usually not required for healthy individuals. However, for those at risk, healthcare providers may order:
Bismuth Subcitrate may cause dizziness or temporary confusion in some patients. Patients should determine how they react to the medication before driving or operating heavy machinery. If neurological symptoms like tremors or loss of balance occur, these activities must be avoided.
While Bismuth Subcitrate itself does not interact directly with alcohol, it is almost always prescribed with metronidazole. Alcohol must be strictly avoided during treatment and for at least 72 hours after the last dose of metronidazole to prevent a disulfiram-like reaction (severe vomiting, flushing, rapid heartbeat, and abdominal cramps).
There is no requirement to taper Bismuth Subcitrate. However, stopping the medication before the full 10-to-14-day course is completed significantly increases the risk that the H. pylori infection will return and become resistant to future antibiotic treatments. Patients should not stop therapy unless directed by a doctor due to a serious side effect.
> Important: Discuss all your medical conditions, especially any history of kidney disease or neurological disorders, with your healthcare provider before starting Bismuth Subcitrate.
For each major interaction, the mechanism usually involves chelation—where the bismuth molecule physically binds to another drug molecule, creating a complex that the body cannot absorb. This results in reduced efficacy of the other medication. Management usually involves spacing doses or choosing alternative therapies.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids and vitamins.
Bismuth Subcitrate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a physician include:
Patients who are allergic to Bismuth Subsalicylate (Pepto-Bismol) should be considered potentially allergic to Bismuth Subcitrate. Although the salts are different, the bismuth ion is the same. Additionally, because Bismuth Subcitrate is almost always used with Metronidazole, patients with a history of nitroimidazole allergy must be identified.
> Important: Your healthcare provider will evaluate your complete medical history, especially your kidney health and allergy profile, before prescribing Bismuth Subcitrate.
Bismuth Subcitrate is generally categorized as Pregnancy Category D when used in combination with tetracycline. There is limited data on Bismuth Subcitrate as a standalone agent in humans, but animal studies have suggested potential embryotoxicity at high doses. Because H. pylori eradication is rarely an emergency, treatment is typically delayed until after delivery. If treatment is absolutely necessary during pregnancy, alternative regimens that do not include bismuth or tetracycline are usually preferred.
It is unknown whether bismuth is excreted in human breast milk. However, many of the drugs used alongside Bismuth Subcitrate (like metronidazole) do pass into milk and may cause side effects in the nursing infant. Most clinical guidelines recommend either suspending breastfeeding during the 10-to-14-day treatment course or using an alternative treatment that is known to be safer for lactation.
The safety and effectiveness of Bismuth Subcitrate Potassium in pediatric patients (under 18 years of age) have not been established. The primary concern in children is the risk of bismuth accumulation and the potential for Reye's syndrome, a rare but fatal condition that affects the brain and liver. Healthcare providers typically use alternative antibiotic combinations for children with H. pylori.
In patients over 65, the primary concern is age-related decline in renal function. Since bismuth is cleared renally, elderly patients are at a higher risk for toxicity. Clinical studies have shown that the drug is effective in this population, but physicians should calculate Creatinine Clearance before prescribing. There is no evidence that elderly patients require a different dose, provided their kidney function is within an acceptable range.
This is the most critical special population for Bismuth Subcitrate.
No specific dose adjustments are required for patients with liver disease, as bismuth does not undergo hepatic metabolism. However, clinicians must be cautious if the patient has concomitant renal issues (hepatorenal syndrome), as this would contraindicate the use of bismuth.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have any degree of kidney disease.
Bismuth Subcitrate Potassium acts through several distinct pathways to treat gastric disease. Locally, it reacts with gastric acid to form a precipitate of bismuth oxychloride and bismuth citrate. This precipitate has a high affinity for damaged mucosa, where it binds to glycoproteins to form a protective physical barrier against acid and pepsin.
At the antimicrobial level, bismuth disrupts the cell wall of H. pylori, inhibits its protein and nucleic acid synthesis, and interferes with the urease enzyme. By inhibiting urease, bismuth prevents the bacteria from creating the alkaline microenvironment it needs to survive in the stomach's acid. It also prevents bacterial adhesion to the gastric epithelium, making it easier for co-administered antibiotics to clear the infection.
The pharmacodynamic effect of Bismuth Subcitrate is primarily local within the stomach. The onset of the protective coating is rapid, occurring within minutes of ingestion. The duration of the antimicrobial effect lasts as long as the bismuth remains in contact with the gastric mucosa, which is why four-times-daily dosing is required. Tolerance to the antimicrobial effects of bismuth has not been reported, making it a valuable tool against antibiotic-resistant H. pylori.
| Parameter | Value |
|---|---|
| Bioavailability | < 1% (systemic) |
| Protein Binding | > 90% |
| Half-life (Terminal) | 21 - 72 days |
| Tmax | 0.5 - 2 hours |
| Metabolism | None (Elemental) |
| Excretion | Fecal (~99%), Renal (<1%) |
Bismuth Subcitrate is a member of the gastrointestinal mucosal protectants and bismuth-containing antidiarrheals. Within the context of H. pylori therapy, it is considered a key component of 'Bismuth Quadruple Therapy.' Related medications include Bismuth Subsalicylate and Bismuth Subnitrate.
Common questions about Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride
Bismuth Subcitrate is primarily used as a critical component in the eradication of Helicobacter pylori (H. pylori) bacteria, which is a leading cause of stomach ulcers and gastritis. It works by coating the stomach lining to protect ulcers from acid and by directly killing the bacteria through the disruption of their cell walls and enzymes. Healthcare providers typically prescribe it as part of a 'quadruple therapy' that includes two other antibiotics and an acid-suppressing proton pump inhibitor. It may also be used off-label to treat symptoms of indigestion or dyspepsia. Because it is highly effective against antibiotic-resistant strains, it is a cornerstone of modern gastroenterology.
The most common side effect of Bismuth Subcitrate is a harmless blackening of the stools, which occurs in the majority of patients. This happens because bismuth reacts with sulfur in your digestive tract to form bismuth sulfide, a dark pigment. You may also notice a temporary darkening of the tongue or a metallic taste in your mouth. Other frequent side effects include mild nausea, diarrhea, or abdominal discomfort, often due to the combination of medications used in the treatment regimen. These effects are temporary and typically disappear within a few days of finishing the medication. If you experience severe constipation or persistent vomiting, you should contact your doctor.
You must strictly avoid alcohol while taking Bismuth Subcitrate if it is part of a combination therapy containing metronidazole. Alcohol reacts with metronidazole to cause a 'disulfiram-like reaction,' which includes severe nausea, projectile vomiting, flushing, rapid heartbeat, and throbbing headaches. This warning applies to all forms of alcohol, including beer, wine, spirits, and even alcohol-containing mouthwashes or cough syrups. You should continue to avoid alcohol for at least 72 hours after your last dose of the medication to ensure it has completely cleared your system. Always check with your pharmacist to see if your specific bismuth regimen includes metronidazole.
Bismuth Subcitrate is generally not recommended during pregnancy, especially during the third trimester. Most clinical guidelines suggest delaying the treatment of H. pylori until after delivery unless the mother's health is at significant risk. This is because bismuth can be absorbed in small amounts, and its long-term effects on fetal development are not fully understood. Furthermore, bismuth is almost always prescribed with tetracycline, which is known to cause permanent tooth discoloration and bone growth issues in the fetus. If you are pregnant or planning to become pregnant, your doctor will likely choose an alternative treatment or wait until after you have given birth.
Bismuth Subcitrate begins working locally in the stomach almost immediately after the first dose by forming a protective layer over the gastric mucosa. However, the full antimicrobial effect required to kill H. pylori takes much longer, which is why a full 10-to-14-day course is mandatory. Most patients begin to feel relief from ulcer-related pain or indigestion within 3 to 5 days of starting therapy. It is vital not to stop taking the medication just because you feel better, as the bacteria may not be fully eradicated. A follow-up test is usually performed four weeks after the treatment ends to confirm the infection is gone.
While you can physically stop taking Bismuth Subcitrate without experiencing withdrawal symptoms, doing so before the end of your prescribed 10-to-14-day course is highly discouraged. Stopping early allows the H. pylori bacteria to survive and potentially develop resistance to the antibiotics you are taking. This makes the infection much harder to treat in the future and increases the risk of your stomach ulcer returning or complications like gastric cancer developing. You should only stop the medication early if you experience a serious allergic reaction or neurological symptoms, and only after consulting your healthcare provider. Completing the entire course is the best way to ensure a permanent cure.
If you miss a dose of Bismuth Subcitrate, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, simply skip the missed dose and continue with your regular schedule. Never take two doses at once to make up for a missed one, as this can increase the risk of side effects or bismuth accumulation. If you find yourself missing multiple doses, contact your doctor, as the effectiveness of the H. pylori eradication therapy depends on maintaining consistent levels of the medication in your system. Setting an alarm on your phone can help you remember the four-times-daily dosing schedule.
Weight gain is not a recognized side effect of Bismuth Subcitrate. In fact, some patients may experience a slight decrease in appetite or temporary weight loss during the 14-day treatment course due to gastrointestinal side effects like nausea or a metallic taste in the mouth. If you notice significant weight gain while taking this medication, it is likely due to other factors or medications you may be taking. Always report unexpected changes in weight to your healthcare provider, especially if accompanied by swelling in the legs or feet, which could indicate a kidney problem. Bismuth itself does not affect the metabolic processes that lead to fat accumulation.
Bismuth Subcitrate has several significant drug interactions that require careful management. It can bind to other medications in the stomach, such as tetracycline antibiotics and quinolones (like ciprofloxacin), preventing them from being absorbed into your bloodstream. To avoid this, you should generally space these medications at least two hours apart from your bismuth dose. It also interacts with antacids and dairy products, which can change how the bismuth works in your stomach. Always provide your doctor and pharmacist with a full list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking to ensure there are no dangerous interactions.
Bismuth Subcitrate Potassium is available both as a generic medication and as part of brand-name combination products like Pylera. The availability of the standalone generic varies by country; in many regions, it is primarily dispensed as part of the fixed-dose combination capsule to improve patient compliance with the complex H. pylori treatment schedule. Generic versions are required by the FDA to have the same active ingredients, strength, and effectiveness as the brand-name versions. If cost is a concern, ask your pharmacist if a generic alternative is available for your specific prescription.
Other drugs with the same active ingredient (Bismuth Subcitrate)